Drawing for EPIPLEX

USPTO serial 98219259

EPIPLEX

Reviewed by CopyMark Law Group

Reg. 8179160Status 700Registered
Filing date
Status date
Registration date
Mar 17, 2026
Examiner
RUTLAND, BARBARA A
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with EPIPLEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Aydin H. Harston

Aydin H. Harston ROTHWELL, FIGG, ERNST & MANBECK, PC901 NEW YORK AVENUE, N.W.SUITE 900 EASTWASHINGTON, DC 20001

Goods and services

ClassDescriptionStatusFirst use
001Assays and reagents for use in genetic research; Biochemical reagents commonly known as probes, other than for medical or veterinary purposes, for detecting and analyzing molecules in protein or nucleotide arrays; Chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with amplification, analysis or labeling of nucleic acid; Nucleic acid for laboratory use other than for medical or veterinary purposes; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Nucleic acid sequences and chemical reagents for other than medical and veterinary purposes; Reagents for scientific or medical research useACTIVEJul 25, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 17, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 17, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 21, 2026SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Feb 21, 2026CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jan 29, 2026DOCKASSIGNED TO EXAMINER—
Jan 21, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jan 21, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 12, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 12, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 12, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 16, 2025IUAFUSE AMENDMENT FILED—
Jul 16, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Feb 25, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 31, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 31, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 25, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 4, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 3, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 3, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 3, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 3, 2024XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Sep 3, 2024XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jun 5, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 30, 2024DOCKASSIGNED TO EXAMINER—
Oct 16, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 14, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance